Related Experiment Videos
Multiple actions of somatostatin in neoplastic disease
1Division of Cell Biology, University of Berne, Switzerland.
Abstract:
The role played by the neuropeptide somatostatin, also known as somatotropin release inhibitory factor (SRIF), in human cancer is not well understood. Recent investigations involving somatostatin receptors in normal and neoplastic human tissues suggest that the action is complex and involves both direct and indirect mechanisms. In this article, Jean-Claude Reubi and Jean Laissue describe the variety of biological mechanisms involved in neoplasia that are associated with somatostatin, and illustrate the therapeutic potential and present limitations of somatostatin analogues.
Insights
The neuropeptide somatostatin (SRIF) has complex roles in human cancer, involving direct and indirect mechanisms. Further research into somatostatin analogues may offer therapeutic potential but also presents limitations.
Area of Science:
- Endocrinology
- Oncology
- Neuroscience
Background:
- The role of the neuropeptide somatostatin (SRIF) in human cancer remains incompletely understood.
- Somatostatin receptors are present in both normal and neoplastic human tissues, indicating a complex involvement.
- Previous research suggests both direct and indirect mechanisms mediate somatostatin's action in cancer.
Purpose of the Study:
- To elucidate the diverse biological mechanisms of somatostatin in neoplasia.
- To explore the therapeutic potential of somatostatin analogues in cancer treatment.
- To outline the current limitations associated with somatostatin analogue therapy.
Main Methods:
- Review of existing literature on somatostatin and cancer.
- Analysis of somatostatin receptor expression in normal and neoplastic tissues.
- Evaluation of biological mechanisms linking somatostatin to neoplasia.
Main Results:
- Somatostatin's role in cancer involves a variety of complex biological mechanisms.
- Somatostatin analogues show promise as a therapeutic strategy.
- Significant limitations exist in the current application of somatostatin analogues.
Conclusions:
- Somatostatin plays a multifaceted role in human cancer.
- Somatostatin analogues represent a potential therapeutic avenue with associated challenges.
- Further investigation is warranted to optimize somatostatin-based cancer therapies.